ATE536186T1 - Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel - Google Patents

Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel

Info

Publication number
ATE536186T1
ATE536186T1 AT04817764T AT04817764T ATE536186T1 AT E536186 T1 ATE536186 T1 AT E536186T1 AT 04817764 T AT04817764 T AT 04817764T AT 04817764 T AT04817764 T AT 04817764T AT E536186 T1 ATE536186 T1 AT E536186T1
Authority
AT
Austria
Prior art keywords
insulin
growth factor
deficiency
igf
treatment
Prior art date
Application number
AT04817764T
Other languages
English (en)
Inventor
Ross G Clark
Original Assignee
Tercica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tercica Inc filed Critical Tercica Inc
Application granted granted Critical
Publication of ATE536186T1 publication Critical patent/ATE536186T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04817764T 2003-09-12 2004-09-09 Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel ATE536186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50257903P 2003-09-12 2003-09-12
PCT/US2004/029735 WO2005049792A2 (en) 2003-09-12 2004-09-09 Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency

Publications (1)

Publication Number Publication Date
ATE536186T1 true ATE536186T1 (de) 2011-12-15

Family

ID=34619295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04817764T ATE536186T1 (de) 2003-09-12 2004-09-09 Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel

Country Status (18)

Country Link
US (3) US7258864B2 (de)
EP (2) EP2274978B1 (de)
JP (1) JP4738337B2 (de)
CN (2) CN1870893A (de)
AT (1) ATE536186T1 (de)
AU (1) AU2004291833B2 (de)
CA (1) CA2538342C (de)
DK (1) DK2274978T3 (de)
ES (2) ES2541673T3 (de)
HU (1) HUE027218T2 (de)
IL (1) IL174209A (de)
MA (1) MA28091A1 (de)
NZ (1) NZ545940A (de)
PL (1) PL2274978T3 (de)
PT (1) PT2274978E (de)
TN (1) TNSN06082A1 (de)
WO (1) WO2005049792A2 (de)
ZA (1) ZA200602183B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536186T1 (de) * 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
JP2008545752A (ja) * 2005-06-02 2008-12-18 テルシカ インコーポレーティッド 成長障害を処置するための方法
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
CA2643529C (en) * 2008-11-06 2019-05-21 Kenneth W. Adams Method and composition for enhancement of male erectile function
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
BR112012001363A2 (pt) 2009-07-22 2016-11-08 Ipsen Pharma Sas análogo de igf-1, composição farmacêutica,e, método para tratar condições ou doenças mediadas pela ligação do receptor de igf-1
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2011150228A1 (en) * 2010-05-26 2011-12-01 The Children's Hospital Of Philadelphia Research Institute Compositions and methods for the diagnosis and treatment of primary insulin-like growth factor deficiency (pigfd) and idiopathic short stature (iss)
WO2012094755A1 (en) * 2011-01-14 2012-07-19 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
EP3233109A4 (de) * 2014-12-16 2018-07-18 Puretein Bioscience, LLC Verfahren zur steigerung des serum-igf-1-spiegels bei einem tier
WO2019075404A2 (en) * 2017-10-13 2019-04-18 The Metrohealth System IGF-1 (INSULIN GROWTH FACTOR) AS A THERAPY FOR CARDIAC ARRHYTHMIAS
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3776801A4 (de) 2018-04-10 2021-12-22 Tandem Diabetes Care, Inc. System und verfahren zum induktiven laden einer medizinischen vorrichtung

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
DE3486216T2 (de) 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPH0720993B2 (ja) 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
ES2007309T3 (es) 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
WO1989005822A1 (en) 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
EP0597033B1 (de) 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
EP0736038B1 (de) 1993-12-23 2001-07-04 Novo Nordisk A/S Verbindungen mit wachstumshormon-freisetzenden eigenschaften
ATE197158T1 (de) 1993-12-23 2000-11-15 Novo Nordisk As Verbindungen mit wachstumshormonfreisetzenden eigenschaften
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
KR100543190B1 (ko) 1995-05-26 2006-06-23 떼라떼끄놀로지 인코퍼레이티드 향상된생물학적효능을갖는키메라성지방체-프로-지알에프유사체
JPH11508608A (ja) 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE60042550D1 (de) 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
ATE536186T1 (de) * 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel

Also Published As

Publication number Publication date
JP4738337B2 (ja) 2011-08-03
AU2004291833B2 (en) 2010-08-26
US20050059598A1 (en) 2005-03-17
US20080058259A1 (en) 2008-03-06
EP2274978A1 (de) 2011-01-19
PT2274978E (pt) 2015-07-09
IL174209A (en) 2012-12-31
US20090270323A1 (en) 2009-10-29
EP2274978B1 (de) 2015-05-20
PL2274978T3 (pl) 2015-11-30
NZ545940A (en) 2009-12-24
US7517530B2 (en) 2009-04-14
WO2005049792A2 (en) 2005-06-02
ZA200602183B (en) 2007-07-25
AU2004291833A1 (en) 2005-06-02
EP1667521B1 (de) 2011-12-07
CN102861321A (zh) 2013-01-09
HUE027218T2 (en) 2016-10-28
WO2005049792A3 (en) 2006-02-23
US8133862B2 (en) 2012-03-13
DK2274978T3 (en) 2015-06-15
JP2007505140A (ja) 2007-03-08
IL174209A0 (en) 2006-08-01
CA2538342C (en) 2013-01-08
TNSN06082A1 (en) 2007-10-03
CA2538342A1 (en) 2005-06-02
EP1667521A2 (de) 2006-06-14
CN1870893A (zh) 2006-11-29
ES2541673T3 (es) 2015-07-23
EP1667521A4 (de) 2008-07-02
MA28091A1 (fr) 2006-08-01
US7258864B2 (en) 2007-08-21
ES2373783T3 (es) 2012-02-08

Similar Documents

Publication Publication Date Title
ATE536186T1 (de) Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
Khandelwal et al. Conventional SLA and chemically modified SLA implants in patients with poorly controlled type 2 diabetes mellitus–a randomized controlled trial
ATE203165T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndromes
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
Yang et al. Sihler-stain study of buccal nerve distribution and its clinical implications
DE69841907D1 (de) Zusammensetzungen enthaltend Capsaicin oder Capsaicin Analoge und ein Anästhetikum
ATE446101T1 (de) Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
Romanos et al. Immediately loaded platform‐switched implants in the anterior mandible with fixed prostheses: a randomized, split‐mouth, masked prospective trial
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
Crescentini et al. Cognitive and brain reserve for mind-body therapeutic approaches in multiple sclerosis: a review
PL374301A1 (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
US6818665B2 (en) Treatment of obstructive sleep apnea
DE60229240D1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
ATE246511T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms
Balaji Total reconstruction of mandible by transport distraction after complete resection for benign and malignant tumors
DE60141759D1 (de) Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
DE60042171D1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
WO2003045322A3 (en) Method for treating and preventing pancreatitis
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
Kulasegaram et al. End-of-Life care communication training programs for Long-Term care staff: A scoping review
Aksoy et al. Distribution and pattern of implant therapy in a part of the Turkish population